SLCO1B1 PCR Assay

Name: SLCO1B1 PCR Assay - Goffin Molecular Technologies
Availability: InStock

Short description

The SLCO1B1 c.521T>C RealFast™ Assay is a PCR test that detects a genetic variant responsible for simvastatin-induced myopathy, a severe side effect of statin treatment. Simvastatin is a widely prescribed statin for reducing LDL cholesterol levels, but its adverse events, including myopathy and rhabdomyolysis, are concerning.

The c.521T>C variant of the SLCO1B1 gene affects the hepatic uptake and metabolism of statins, leading to increased risk of simvastatin-induced myopathy in patients carrying the c.521C allele. The assay identifies the c.521T>C genotype in a human DNA extract, enabling personalized dose adjustment of simvastatin according to CPIC guidelines. Personalized dosing guided by genetic testing improves patient safety and reduces the risk of statin-induced myopathy associated with empirical dosing.

Product highlights

Personalized medicine
Reducing the risk of potentially dangerous side effects
Fast and accurate detection of the SLCO1B1 c.521T>C variant
Can be performed in a standard laboratory setting
Cost-effective solution for determining SLCO1B1 genotype

Ask for a quote

SLCO1B1 PCR Assay

Packaging

Clear

Add to quote

More
information

Downloads

Instructions for Use

SLCO1B1 IFU

Brochure

SLCO1B1 Brochure

MSDS

Safety Data Sheet

Specifications of the SLCO1B1 PCR Assay

Introducing the SLCO1B1 c.521T>C RealFast™ Assay – the fast and accurate PCR test for detecting a genetic variant responsible for simvastatin-induced myopathy, a severe side effect of statin treatment.

Simvastatin is a widely prescribed statin for reducing LDL cholesterol levels, but its dose-dependent adverse events, including myopathy and rhabdomyolysis, are concerning. The c.521T>C variant of the SLCO1B1 gene affects the hepatic uptake and metabolism of statins, leading to increased risk of simvastatin-induced myopathy in patients carrying the c.521C allele.

The SLCO1B1 c.521T>C RealFast™ Assay identifies the c.521T>C genotype in a human DNA extract, enabling personalized dose adjustment of simvastatin according to CPIC guidelines. By avoiding the risk of simvastatin-induced myopathy, patients can benefit from the lipid-lowering effects of statin therapy without experiencing severe side effects.

Trust in Viennalab’s expertise and experience in molecular diagnostics to provide you with reliable and easy-to-use results for your laboratory workflow. Improve patient safety and reduce the risk of statin-induced myopathy associated with empirical dosing – add the SLCO1B1 c.521T>C RealFast™ Assay to your laboratory today.

Components of the SLCO1B1 PCR Assay

DNA Extraction Kit: A kit containing all the reagents necessary for the extraction of genomic DNA from a blood or saliva sample, including DNA extraction buffer, proteinase K, and magnetic beads.
PCR Mix: A ready-to-use mix containing all the reagents necessary for the PCR amplification of the SLCO1B1 gene region of interest.
SLCO1B1 Primer Mix: A mix of primers specific for the SLCO1B1 gene region of interest.
Probe Mix: A mix of probes specific for the detection of SNPs in the SLCO1B1 gene.
Control DNA: A synthetic DNA that is added to the sample as an internal control to ensure that the assay is working correctly.
DNase/RNase-free Water: Water that has been treated to remove contaminating DNases and RNases, which can degrade the extracted DNA.

The kit also includes instructions for use, as well as a protocol for the detection of SNPs in the SLCO1B1 gene using real-time PCR.